Psychedelics sometimes cause bad trips by creating horrible scenarios for some individuals. Rick Doblin, the founder of the Multidisciplinary Association for Psychedelic Studies (“MAPS”), recently talked about difficult trips and how people could be guided through these experiences.
During a recent interview, Doblin, a psychonaut and veteran psychedelic researcher, was asked whether MAPS would start a psychonaut training program based partly on principles of psychedelic harm reduction. Doblin revealed that the program, which was briefly referenced on the MAP’s website, was still being developed but would launch in various parts of North America where psychedelic substances had been decriminalized.
He stated that plant psychedelics were being decriminalized in different areas, noting that he hoped drug-policy reform efforts would be successful. He explained that if individuals in these jurisdictions and areas were experiencing a lot of difficult trips, it could be an issue, which was why the company was developing the training.
The psychonaut training program that MAPS is developing will include various exercises and basic training for individuals who want to help others; the training program takes about 16 hours, after which individuals will be awarded a certificate. Doblin explained that the training would be a guiding tool on how to handle various situations, noting that when guiding an individual through a difficult trip, it is important to talk them through it instead of talking down on it.
The veteran psychedelic researcher has explored psychedelics for most of his life, through a mix of activism, therapy and research. Doblin first experimented with LSD in college then MDMA in the early ‘80s. This was what led to the launch of MAPS in 1986.
MAPS recently completed a phase 3 clinical trial for MDMA, which received approval from the FDA. The trial looked into whether the MDMA, when used in combination with psychotherapy, could decrease PTSD symptom severity. The results from the trial show that two months after the treatment was administered, more than 65% of the participants who received the MDMA treatment no longer experienced post-traumatic stress disorder symptoms.
If the second phase of this trial proves that the drug is indeed effective, Doblin’s dream of having MDMA legalized for therapeutic use in the United States may be granted by the Food and Drug Administration in about two years. Doblin hopes that this approval will extend to Canada, Israel and possibly Australia. He hopes that in the near future England will also follow suit.
As all those jurisdictions enact psychedelic reforms, industry actors such as Delic Holdings Corp. (CSE: DELC) (OTC: DELCF) will have a bigger market to serve.
NOTE TO INVESTORS: The latest news and updates relating to Delic Holdings Corp. (CSE: DELC) (OTCQB: DELCF) are available in the company’s newsroom at https://ibn.fm/DELCF
About PsychedelicNewsWire
PsychedelicNewsWire (PNW) is a specialized content distribution company that (1) aggregates and distributes news and information on the latest developments in all aspects and advances of psychedelics and their use, (2) creates PsychedelicNewsBreaks designed to quickly update investors on important industry news, (3) leverages a team of expert editors to enhance press releases for maximum impact, (4) assists companies with the management and optimization of social media across a range of platforms, and (5) delivers unparalleled corporate communication solutions. PNW stays abreast of the latest information and has established a reputation as the go to source for coverage of psychedelics, therapeutics and emerging market opportunities. Our team of seasoned journalists has a proven track record of helping both public and private companies gain traction with a wide audience of investors, consumers, media outlets and the general public by leveraging our expansive dissemination network of more than 5,000 key syndication outlets. PNW is committed to delivering improved visibility and brand recognition to companies operating in the emerging markets of psychedelics.
To receive instant SMS alerts, text “Groovy” to 888-902-4192 (U.S. Mobile Phones Only)
For more information please visit https://www.psychedelicnewswire.com
Please see full terms of use and disclaimers on the PsychedelicNewsWire website applicable to all content provided by PNW, wherever published or re-published: https://www.psychedelicnewswire.com/Disclaimer
Do you have questions or are you interested in working with PNW? Ask our Editor
PsychedelicNewsWire (PNW)
San Francisco, California
www.psychedelicnewswire.com
415.949.5050 Office
Editor@PsychedelicWire.com
PsychedelicNewsWire is part of the InvestorBrandNetwork.
The acquisition of Cohen and Associates, a respected interventional psychiatry practice, by NRx subsidiary HOPE…
The new FDA voucher program aims to speed approval of drugs aligned with national health…
The company targets all current ketamine indications, including anesthesia and pain management. The U.S. is…
The Kadima Neuropsychiatry Institute acquisition is part of NRx subsidiary HOPE Therapeutics’ model for a…
Subsidiary HOPE Therapeutics signed a $7.8 million debt financing term sheet with Universal Capital. Combined…
Kadima Neuropsychiatry Institute is expected to become the clinical model for HOPE Therapeutics’ nationwide network…